Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 11.07 USD -0.81% Market Closed
Market Cap: 595.9m USD

During the last 3 months Prothena Corporation PLC insiders have not bought any shares, and have not sold any shares. The stock price has increased by 30% over this period (open performance analysis).

The last transaction was made on May 6, 2025 by Ecor1 Capital, Llc , who sold 15.2m USD worth of PRTA shares.

Last Transactions:
Ecor1 Capital, Llc
$-15.2m
Ecor1 Capital, Llc
$-7.9m
Ecor1 Capital, Llc
$-27.7m
Scully William P
$+1.3m
Scully William P
$+16k
Scully William P
$+31.8k
Scully William P
$+1m
Walker Karin L
$-170k
Walker Karin L
$-61.5k
Walker Karin L
$-170k
Walker Karin L
$-72k
Smith Brandon S.
$-165.8k
Karp Carol D.
$-201.7k
Malecek Michael J
$-217.4k
Walker Karin L
$-261.8k
Smith Brandon S.
$-215.6k
Garren Hideki
$-111k
Karp Carol D.
$-273.5k
Malecek Michael J
$-126.7k
Walker Karin L
$-285.9k
Smith Brandon S.
$-129.6k
Garren Hideki
$-51.1k
Zago Wagner M.
$-252.6k
Karp Carol D.
$-312.8k
Malecek Michael J
$-153k
Walker Karin L
$-273.5k
Garren Hideki
$-128.8k
Smith Brandon S.
$-215.7k
Zago Wagner M.
$-203.3k
Karp Carol D.
$-269.6k
Selkoe Dennis J.
$-337.2k
Malecek Michael J
$-85.6k
View All Transactions

During the last 3 months Prothena Corporation PLC insiders have not bought any shares, and have not sold any shares. The stock price has increased by 30% over this period (open performance analysis).

The last transaction was made on May 6, 2025 by Ecor1 Capital, Llc , who sold 15.2m USD worth of PRTA shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
50.8m USD
1
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
1
2.3m USD

Prothena Corporation PLC
Insider Trading Chart

Prothena Corporation PLC
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Prothena Corporation PLC
Last Insider Transactions

Global
Insiders Monitor

Prothena Corporation PLC
Glance View

Market Cap
595.9m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
HIDDEN
Show

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top